Hypoxia can be prevented with oxygen supplementation.Pulmonary fibrosis may also result in an increased risk for pulmonary emboli, which can be prevented by anticoagulants. Epidemiology
Five million people worldwide are affected by pulmonary fibrosis. The rates below are per 100,000 persons, and the ranges reflect narrow and broad inclusion criteria, respectively. These data do not reflect any increased rates due to the COVID-19 pandemic; pulmonary fibrosis is a known symptom of COVID-19 and is estimated (as of July 2020) to occur in roughly 1/3rd of patients hospitalized for COVID-19. Based on these rates, pulmonary fibrosis prevalence in the United States could range from more than 29,000 to almost 132,000, based on the population in 2000 that was 18 years or older. The actual numbers may be significantly higher due to misdiagnosis. Typically, patients are in their forties and fifties when diagnosed while the incidence of idiopathic pulmonary fibrosis increases dramatically after the age of fifty. However, loss of pulmonary function is commonly ascribed to old age, heart disease or to more common lung diseases. References


== External links ==
Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.It is a recombinant enzyme that is administered weekly by intramuscular injection.Elapegademase may interact with PEGylated drugs.Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018. Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program. References
External links
"Elapegademase". Drug Information Portal. U.S. National Library of Medicine.